Intercept Pharmaceuticals Inc to Present two Poster Presentations; Wedbush Remains Positive
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares are up 2.46% today, as the company will present two poster presentations highlighting new subgroup analyses from the Phase 2b FLINT trial of OCA in patients with NASH at the American Association for the Study of Liver Disease (AASLD) and Industry Colloquium. The company will host an Investor Event today at 6:00 pm ET / 3:00 pm PT to discuss the two posters.
Subsequently, Wedbush analyst Liana Moussatos came out with a research note on ICPT ahead of these events. She noted, "These data further validate the benefits of OCA in decreasing liver-related adverse events in high-risk populations, improving long-term cardiovascular risk and, when combined with statins, improving LDL levels."
The analyst rates ICPT an Outperform with a price target/acquisition value of $493, which represents a 66% gain from current levels.
According to TipRanks.com, which measures analysts' and bloggers' success rate based on how their calls perform, analyst Liana Moussatos has a total average return of 57.1% and a 78.8% success rate. Moussatos has a 159.9% average return when recommending ICPT, and is ranked #1 out of 3535 analysts.